Ruud Dobber, Ph.D

Executive Vice President and President, BioPharmaceuticals Business Unit

Responsibilities

Ruud was appointed Executive Vice President (EVP) and President, BioPharmaceuticals Business Unit in January 2019 and is responsible for product strategy and commercial delivery for Cardiovascular, Renal & Metabolism (CVRM) and Respiratory diseases. 

Prior experience

Prior to this, Ruud held the role of EVP, North America since August 2016. Ruud joined Astra in 1997 (before the AstraZeneca merger) and has held various senior commercial and leadership roles, including as EVP, Europe, Regional Vice President of AstraZeneca’s European, Middle East and African division, Regional Vice President for the Asia Pacific region and Interim Executive Vice President, Global Product and Portfolio Strategy. 

Ruud was appointed as a non-executive director of the Board of Almirall in June 2021. He was a member of the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and was previously Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America.

Education

  • Doctorate in Immunology, University of Leiden, Netherlands
Ruud Dobber

Ruud Dobber, Ph.D JPG 5,355KB

Global leadership team

Our leadership, which includes our Board of Directors and Senior Executive Team represents the interests of all our stakeholders in ensuring that we deliver for patients by putting science at the heart of everything we do.

What science can do

Stories from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.

Our company

We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.